Home / Market News / $HOWL
fiscal.ai Corporate Catalyst Impact 75/100 ● neutral

Werewolf Therapeutics Announces Clinical Data for WTX-124 and WTX-330

Nov 10, 2026, 2:18 PM UTC · Primary ticker $HOWL

Werewolf Therapeutics announced positive clinical data for two of its drug candidates, WTX-124 and WTX-330, showing clinical activity and good tolerability in advanced cancer patients. The company also aligned with the FDA on a recommended Phase 2 dose for WTX-124, which is a significant de-risking event for the program and could lead to further development opportunities.

Werewolf Therapeutics reported encouraging Phase 1/1b and Phase 1b/2 clinical data for its drug candidates, WTX-124 and WTX-330, respectively. The data, presented at SITC 2026, indicated clinical activity and good tolerability in patients with advanced, treatment-refractory disease, administered in an outpatient setting without severe adverse events. This positive clinical update, coupled with the FDA's alignment on a recommended Phase 2 dose for WTX-124, significantly de-risks the development pathway for this program. For traders, this news presents a short-term opportunity for a positive stock reaction for HOWL due to the improved outlook for its pipeline. Long-term implications include potential for accelerated development and future commercialization, though further successful clinical trials are still required. The key opportunity lies in the validation of their therapeutic approach and the clear path forward for WTX-124.

$HOWL positive Positive clinical data and FDA alignment for key drug candidates
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.